G+FLAS Life Sciences
Korean biotech company (founded 2014) focused on CRISPR-based genome editing platforms and plant-based biomanufacturing. Core activities include development of engineered nuclease variants and genome-editing molecules, DNA-free plant genome-editing workflows, plant-expression and glyco‑engineering for biologics, production and global distribution of CRISPR enzyme reagents, GMP reagent manufacturing and facility development, contract genome-editing and protein expression services, and technology licensing and industry partnerships. The company maintains an active patent portfolio and participates in industry consortia.
Industries
Nr. of Employees
small (1-50)
G+FLAS Life Sciences
Osong branch: 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28161, Korea
Patents
Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients
US-11865164-B2
View Details
Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients
US-11865164-B2
View DetailsProducts
Purified CRISPR nuclease reagents and enzyme variants
Cataloged purified nuclease reagents and enzyme variants provided in multiple formulations and package sizes for research genome-editing workflows.
Plant-based glycoengineered biologics production platform
Platform for producing glycoengineered monoclonal antibodies, antigens, enzymes and therapeutic proteins in plant hosts, with upstream controlled-environment processing.
Controlled-environment cultivation and upstream processing systems
Integrated cultivation and upstream processing systems (closed-facility 'plant hotel') for reproducible plant-derived biologics production.
Purified CRISPR nuclease reagents and enzyme variants
Cataloged purified nuclease reagents and enzyme variants provided in multiple formulations and package sizes for research genome-editing workflows.
Plant-based glycoengineered biologics production platform
Platform for producing glycoengineered monoclonal antibodies, antigens, enzymes and therapeutic proteins in plant hosts, with upstream controlled-environment processing.
Controlled-environment cultivation and upstream processing systems
Integrated cultivation and upstream processing systems (closed-facility 'plant hotel') for reproducible plant-derived biologics production.
Services
Contract service for DNA-free genome editing in plants using protoplast-based workflows and CRISPR component delivery to generate edited lines without foreign DNA integration.
Development services for genome-editing applications in mammalian cells including guide design, delivery selection, and molecular validation.
Expression and production services for recombinant proteins, antigens, enzymes and monoclonal antibodies in plant systems with glycosylation modification capability.
Partnerships and licensing arrangements for CRISPR technologies, plant breeding rights, and joint-development programs with industry and academic partners.
Contract service for DNA-free genome editing in plants using protoplast-based workflows and CRISPR component delivery to generate edited lines without foreign DNA integration.
Development services for genome-editing applications in mammalian cells including guide design, delivery selection, and molecular validation.
Expression and production services for recombinant proteins, antigens, enzymes and monoclonal antibodies in plant systems with glycosylation modification capability.
Partnerships and licensing arrangements for CRISPR technologies, plant breeding rights, and joint-development programs with industry and academic partners.
Expertise Areas
- Genome-editing platform development
- Plant-based biomanufacturing
- Glyco‑engineering for biologics
- DNA-free plant genome editing and non‑GMO breeding
Key Technologies
- CRISPR-based nuclease engineering
- Ribonucleoprotein (RNP) delivery
- Viral vector delivery
- Lipid nanoparticle and liposome delivery
News & Updates
Announcement of the company's first delivery of domestically produced CRISPR nuclease enzyme reagents (first commercial sale and delivery event).
Technology transfer/licensing of vitamin D3 tomato trait to Bayer Crop Science (press coverage of license agreement).
Press announcements describing licensing of CRISPR technologies to multiple partners including companies developing CAR-T and other cell therapies.
Multiple patents registered covering engineered CRISPR nucleases, CRISPR-based oncology platform, plant-based biomanufacturing methods, and controlled-environment production systems.
US patent registration announced for a CRISPR-based platform designed to selectively kill cancer cells (press release).
US patent obtained for an engineered CRISPR technology reported to increase editing performance (press release and filings).
Announcement of the company's first delivery of domestically produced CRISPR nuclease enzyme reagents (first commercial sale and delivery event).
Technology transfer/licensing of vitamin D3 tomato trait to Bayer Crop Science (press coverage of license agreement).
Press announcements describing licensing of CRISPR technologies to multiple partners including companies developing CAR-T and other cell therapies.
Multiple patents registered covering engineered CRISPR nucleases, CRISPR-based oncology platform, plant-based biomanufacturing methods, and controlled-environment production systems.
US patent registration announced for a CRISPR-based platform designed to selectively kill cancer cells (press release).
US patent obtained for an engineered CRISPR technology reported to increase editing performance (press release and filings).